Globe News Wire
21 May 2026, 00:21 UTC · 18w ago
Verdict
Headline takes no side. We score RLAY −0.20 across three claims — slightly bearish.
−0.20slightly bearish
More negative than 67% of ticker scores this week
What the story claims
3 claims · scored −1 bearish … +1 bullish
Relay Therapeutics is conducting a public offering of 22,916,667 shares of common stock at $12.00 per share.
So whatPublic offerings increase share supply and typically lead to immediate equity dilution for existing shareholders.
More negative than 95% of claims this week
The company expects to raise approximately $275 million in gross proceeds from the offering.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 2 movers · tap to explore
More positive than 64% of claims this week
Underwriters have been granted a 30-day option to purchase up to an additional 3,437,500 shares.
So whatThe potential for further share issuance creates additional overhead for potential future dilution.
More negative than 71% of claims this week
Which stocks this story touches
More negative than 67% of ticker scores this week
The company is pricing a public offering of common stock, which typically leads to share dilution for existing investors.
More positive than 47% of ticker scores this week
Goldman Sachs is acting as a joint book-running manager for the offering, generating fee income.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
GlobeNewsWire
13h ago
+38.5%
Price is moving against the score
$18.03 vs $13.02 close before publication (May 20) · not market-adjusted
RLAY chart →
